225 related articles for article (PubMed ID: 20185602)
21. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of epoetin alfa administered every 2 weeks to maintain hemoglobin and quality of life in anemic HIV-infected patients.
Levine AM; Salvato P; Leitz GJ;
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):131-9. PubMed ID: 18284320
[TBL] [Abstract][Full Text] [Related]
23. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease.
Provenzano R; Garcia-Mayol L; Suchinda P; Von Hartitzsch B; Woollen SB; Zabaneh R; Fink JC;
Clin Nephrol; 2004 Jun; 61(6):392-405. PubMed ID: 15224803
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
Carrera F; Oliveira L; Maia P; Mendes T; Ferreira C
Nephrol Dial Transplant; 2006 Oct; 21(10):2846-50. PubMed ID: 16891642
[TBL] [Abstract][Full Text] [Related]
25. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
[TBL] [Abstract][Full Text] [Related]
26. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
Shasha D; George MJ; Harrison LB
Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
[TBL] [Abstract][Full Text] [Related]
27. Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.
Krause MW; Raja R; Agarwal A; Silver MR; Scarlata D; Sciarra A; Kewalramani R
Drugs Aging; 2009; 26(8):665-75. PubMed ID: 19685932
[TBL] [Abstract][Full Text] [Related]
28. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration.
Locatelli F; Villa G; de Francisco AL; Albertazzi A; Adrogue HJ; Dougherty FC; Beyer U;
Curr Med Res Opin; 2007 May; 23(5):969-79. PubMed ID: 17519064
[TBL] [Abstract][Full Text] [Related]
29. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
Abdelrazik N; Fouda M
Hematology; 2007 Dec; 12(6):533-41. PubMed ID: 17852440
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
31. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
Agarwal A; Silver MR; Walczyk M; Liu W; Audhya P
J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537
[TBL] [Abstract][Full Text] [Related]
32. C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
Bastos K; Lucarelli LA; De Francesco-Daher E; Filho RP; Henríquez C; Espinoza B; Villanueva I; Schwedt E; Schiavelli R; Correa-Rotter R
Int Urol Nephrol; 2013 Oct; 45(5):1355-64. PubMed ID: 22990412
[TBL] [Abstract][Full Text] [Related]
33. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.
Warady BA; Barcia J; Benador N; Jankauskiene A; Olson K; Podracka L; Shavkin A; Srivaths P; Wong CJ; Petersen J
Pediatr Nephrol; 2018 Jan; 33(1):125-137. PubMed ID: 28815341
[TBL] [Abstract][Full Text] [Related]
34. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
[TBL] [Abstract][Full Text] [Related]
35. Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis.
Nagaya H; Inaguma D; Kitagawa A; Murata M; Kamimura Y; Hamaguchi K; Tatematsu M; Suzuki S; Kurata K; Yuzawa Y; Matsuo S
Clin Exp Nephrol; 2010 Apr; 14(2):158-63. PubMed ID: 19967423
[TBL] [Abstract][Full Text] [Related]
36. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
Mann J; Kessler M; Villa G; Martinez-Castelao A; Feldt-Rasmussen B; Cruz J; Hörl WH; Mattin C; Praml C; Wilkie M
Clin Nephrol; 2007 Mar; 67(3):140-8. PubMed ID: 17390738
[TBL] [Abstract][Full Text] [Related]
37. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
Duh MS; Mody SH; McKenzie RS; Lefebvre P; Gosselin A; Bookhart BK; Piech CT
Drugs Aging; 2006; 23(12):969-76. PubMed ID: 17154661
[TBL] [Abstract][Full Text] [Related]
38. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.
Roger SD; Locatelli F; Woitas RP; Laville M; Tobe SW; Provenzano R; Golper TA; Ruangkanchanasetr P; Lee HY; Wu KD; Nowicki M; Ladanyi A; Martínez-Castelao A; Beyer U; Dougherty FC
Nephrol Dial Transplant; 2011 Dec; 26(12):3980-6. PubMed ID: 21505096
[TBL] [Abstract][Full Text] [Related]
39. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
[TBL] [Abstract][Full Text] [Related]
40. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
Waltzman R; Croot C; Justice GR; Fesen MR; Charu V; Williams D
Oncologist; 2005 Sep; 10(8):642-50. PubMed ID: 16177289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
